Blueprint Medicines (BPMC) reported 71.96millioninrevenueforthequarterendedDecember2023,representingayear−over−yearincreaseof85.61.82 for the same period compares to -2.65ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof67.28 million, representing a surprise of +6.95%. The company delivered an EPS surprise of +10.78%, with the consensus EPS estimate being -$2.04.While investors closely watch year-over-year changes in headline numbers -- revenue and e ...